Q32 Bio

More About the Company

Status:

Technology Type:

Active

Pharma

Fund:

Fund I

CU Anschutz Medical Campus Spinout:

Yes

Headquarters
Location:

Waltham, MA, USA

Autoimmune Disease Treatments

Based on its next generation complement therapeutic platform, Q32 Bio seeks to commercialize a robust pipeline of complement-based immunotherapies and linked imaging diagnostics to treat several diseases, starting with the orphan indications C3 Glomerulopathy (C3G) and Lupus Nephritis.

Q32 Bio is a CU Anschutz Startup

View their website